CLAIMS

What is claimed is:

1. A compound comprising



or a pharmaceutically acceptable salt or a prodrug thereof;

wherein a dashed line represents the presence or absence of a double bond or a triple bond;

A is $-(CH_2)_6-$, *cis* $-CH_2CH=CH-(CH_2)_3-$, or $-CH_2C\equiv C-(CH_2)_3-$, wherein 1 or 2 carbon atoms may be substituted with S or O;

X is selected from the group consisting of CO_2H, $CONHR_2$, $CONR_2$, $CON(OR)R$, $CON(CH_2CH_2OH)_2$, $CONH(CH_2CH_2OH)$, CH_2OH, $P(O)(OH)_2$, $CONHSO_2R$, SO_2NR_2, SO_2NHR, and



;

J is C=O, CHOH, or CH_2CHOH;

R is independently H, C_1-C_6 alkyl, phenyl, or biphenyl; and

E is C_3-C_6 alkyl, C_4-C_{10} cycloalkyl, phenyl or napthyl having from 0 to 2 substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein said substituents comprise up to 4 non-hydrogen atoms.

2. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

3. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

4. The compound of claim 3 wherein J is C=O.

5. The compound of claim 3 wherein J is CHOH.

6. The compound of claim 3 wherein X is CO_2H.

7. The compound of claim 3 wherein E is phenyl, thienyl, furyl, pyridinyl, napthyl, benzothienyl, or benzofuryl having from 0 to 2 substituents comprising up to 4 non-hydrogen atoms.

8. The compound of claim 3 wherein E is *n*-butyl.

9. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

10. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

11. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

12. A liquid composition comprising



or a pharmaceutically acceptable salt or a prodrug thereof;

wherein a dashed line represents the presence or absence of a double bond or a triple bond;

A is $-(CH_2)_6-$, *cis* $-CH_2CH=CH-(CH_2)_3-$, or $-CH_2C\equiv C-(CH_2)_3-$, wherein 1 or 2 carbon atoms may be substituted with S or O;

X is selected from the group consisting of CO_2H, $CONHR_2$, $CONR_2$, $CON(OR)R$, $CON(CH_2CH_2OH)_2$, $CONH(CH_2CH_2OH)$, CH_2OH, $P(O)(OH)_2$, $CONHSO_2R$, SO_2NR_2, SO_2NHR, and


;

J is C=O, CHOH, or CH_2CHOH;

R is independently H, C_1-C_6 alkyl, phenyl, or biphenyl; and

E is C_3-C_6 alkyl, C_4-C_{10} cycloalkyl, phenyl or napthyl having from 0 to 2 substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein said substituents comprise up to 4 non-hydrogen atoms;

wherein said liquid is formulated for ophthalmic use.

13. A method comprising administering a compound to a mammal, wherein said method is useful for the treatment of glaucoma or ocular hypertension in said mammal, said compound comprising



or a pharmaceutically acceptable salt or a prodrug thereof;

wherein a dashed line represents the presence or absence of a double bond or a triple bond;

A is $-(CH_2)_6-$, *cis* $-CH_2CH=CH-(CH_2)_3-$, or $-CH_2C\equiv C-(CH_2)_3-$, wherein 1 or 2 carbon atoms may be substituted with S or O;

X is selected from the group consisting of CO_2H, $CONHR_2$, $CONR_2$, $CON(OR)R$, $CON(CH_2CH_2OH)_2$, $CONH(CH_2CH_2OH)$, CH_2OH, $P(O)(OH)_2$, $CONHSO_2R$, SO_2NR_2, SO_2NHR, and



;

J is C=O, CHOH, or CH_2CHOH;

R is independently H, C_1-C_6 alkyl, phenyl, or biphenyl; and

E is C_3-C_6 alkyl, C_4-C_{10} cycloalkyl, phenyl or napthyl having from 0 to 2 substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein said substituents comprise up to 4 non-hydrogen atoms.